CN1040923A - Serum composite and compound method thereof - Google Patents
Serum composite and compound method thereof Download PDFInfo
- Publication number
- CN1040923A CN1040923A CN89103922A CN89103922A CN1040923A CN 1040923 A CN1040923 A CN 1040923A CN 89103922 A CN89103922 A CN 89103922A CN 89103922 A CN89103922 A CN 89103922A CN 1040923 A CN1040923 A CN 1040923A
- Authority
- CN
- China
- Prior art keywords
- serum
- swine
- fever
- milliliters
- unit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention is the compound method of the serum composite of treatment swine fever, and described prescription is by aseptic swine fever serum, adds the compound of sodium benzoate, penicillin, streptomycin or the chloromycetin of some in proportion.The simple preparation method of production for treating swine fever serum is provided.These goods and antibiotics are used, and are mainly used in treatment swine fever disease, and its cure rate 97.7% also acts on treatment pig bacillary dysentery, pig lung plague, diseases such as Streptococcus suis, pig erysipelas, and act on and augment the pig body immunologic function, keep off infection, improve the rate of putting on flesh.
Description
The present invention relates to a kind of serum composite and compound method thereof that is used for the treatment of swine fever.
Swine fever is a kind of hyperinfection and very high disease of mortality rate that is caused by swine fever virus, people are developing the active drug that can be used to control anti-swine fever disease always, up to the present only develop the hog cholera lapinised virus vaccine and the anti-swine-fever serum that act on epidemic prevention, the rules of the issuing standard NY43-84 of Ministry of Agriculture, Animal Husbandry and Fisheries of country, the anti-swine-fever serum manufacture method has been proposed, this method is that swine fever virus is expelled on the healthy responsive pig body, carry out fundamental immunity earlier, remake hyperimmunization then, the separation of serum of taking a blood sample at last, because producing of this product requires the above swine fever virus of injection secondary, produce complicated, this serum product usefulness of urgent prevention when popular as swine fever only simultaneously, so the domestic production that always stops these goods.
The object of the present invention is to provide a kind of serum composite and compound method thereof of manufacturing simply and can treating the swine fever disease.
The cause of disease of swine fever is a swine fever virus, and the sick pig that infects swine fever in the course of disease bacillary caused complication can take place, and the medicine that the applicant finds to add antibiotics in anti-swine-fever serum and suppresses virus can reach the effect of treatment swine fever disease.
The virus that the present invention uses is to connect for causing the weak poison of weak swine fever through rabbit.The compound method of serum composite is as follows:
At first, select mn health pig more than 60 kilograms, take intramuscular injection or intravenous method to carry out immunity with poison a little less than the swine fever, as the case may be, after 10～20 days, do immunity for the second time, count with inoculation for the first time, blood sampling after 35 days, adopt blood pack in the vial of cleaning sterile, the blood sampling back checks that the pig body has not eqpidemic disease, if any, blood is discarded.
Then, the blood of taking is coagulated the method separation of serum with condense naturally pressurization or system, draw the supernatant, place 2～15 ℃ of environment, make steriling test, as serum by living contaminants, filter with seitz filter, remake steriling test, thereby it is standby to make aseptic anti-swine-fever serum.
At last, in any order, in aseptic anti-swine-fever serum, add sodium benzoate, penicillin, streptomycin or chloromycetin, carbolic acid, fully shake up, be serum composite of the present invention to dissolving fully.It specifically consists of and adds 2～8 gram sodium benzoate, 40～1,800,000 unit penicillins, 50～1,600,000 unit streptomycin or chloromycetin, 2～5 milliliter 0.3～0.5% carbolic acid in per 500 milliliters of aseptic anti-swine-fever serums.A kind of material of every adding shakes serum gently, treat to continue to add another kind of material after the dissolving fully, but two kinds of antibiotics can once add again, all add shake up after, be serum composite of the present invention, with its sealed packaging, 2～8 ℃ of preservations.
The serum composite of gained of the present invention has the effect of antimicrobial and enhancing pig body complement.This product and antibiotics are used treatment swine fever disease, through clinical proof effective percentage 97.7%, and act on diseases such as treatment pig bacillary dysentery, pig lung plague, Streptococcus suis, pig erysipelas, and act on the pig body immunologic function, keep off infection, and improve the rate of putting on flesh.This method is than simple, the easy row of the method for original production anti-swine-fever serum.
The present invention is further described by the following embodiment.
Embodiment 1:
Select mn health pig more than 60 kilograms, quarantine,, confirm its health, give the pig muscle injection hog cholera lapinised virus at least 100 minimum immunity amounts as no abnormal.After the day of inoculation is counted 35 days, adopt blood with the sterile working through the pig of immunity, be loaded in the vial, check the pig body, if any eqpidemic disease, then adopt blood discarded.
With adopt blood with the pressurization separation of serum that condenses naturally, draw the supernatant, make sterility test, and serum placed 2～15 ℃ of preservations.
Through check, as serum by living contaminants, filter with seitz filter, the recast steriling test adds 6 gram sodium benzoate in checking per 500 milliliters of aseptic serum, shake gently, with its whole dissolvings, add 800,000 unit penicillins and 600,000 unit streptomycins again, shake up, add 3.5 milliliters of 0.3% carbolic acids at last, shake up and be serum composite of the present invention.
Embodiment 2:
Among the embodiment 1, replace 600,000 unit streptomycins with 600,000 unit chloromycetin and add in the anti-swine-fever serum.
Embodiment 3:
Among the embodiment 1, poison is back 20 days a little less than the injection swine fever, injects the weak poison of swine fever more once.After making anti-swine-fever serum, add 1,200,000 unit penicillins and 1,200,000 unit chloromycetin in per 500 milliliters of serum, shake gently and make its dissolving, add 3 gram sodium benzoate again, shake its dissolving, add 2 milliliter 0.5% carbolic acid at last, shake up.
Embodiment 4:
The step of front is used separation of serum instead with embodiment 1, to through checking aseptic serum, per 500 milliliters add 800,000 unit penicillins and 500,000 unit chloromycetin, shake to cause it and be dissolved in serum, add 6 gram sodium benzoate again, shake up, add 0.4% 3.5 milliliters of carbolic acids at last, shake up.
Embodiment 5:
After making anti-swine-fever serum by embodiment 3, add 800,000 unit streptomycins and 1,600,000 unit penicillins in per 500 milliliters of serum, shake up, add 4.5 gram sodium benzoate again, shake up, add 5 milliliter 0.35% carbolic acid at last, shake up and get final product.
Embodiment 6:
After making anti-swine-fever serum by embodiment 3, add 2.5 milliliter 0.5% carbolic acid in per 500 milliliters of serum, shake up, add 8 gram sodium benzoate again, shake up, add 1,200,000 unit chloromycetin then, shake up, add 400,000 unit penicillins at last, fully shake up and get final product.
Claims (8)
1, a kind of serum composite for the treatment of swine fever, Main Ingredients and Appearance is aseptic anti-swine-fever serum, it is characterized in that: specifically consist of per 500 milliliters aseptic anti-swine-fever serum and add 2～8 gram sodium benzoate, 40～1,800,000 unit penicillins, the carbolic acid of 50～1,600,000 unit streptomycins or chloromycetin and 2～5 milliliter 0.3～0.5%.
2, serum composite according to claim 1 is characterized in that: add 6 gram sodium benzoate in per 500 milliliters anti-swine-fever serum, 800,000 unit penicillins, 3.5 milliliters of 600,000 unit streptomycins and 0.3% carbolic acids.
3, serum composite according to claim 1 is characterized in that: add 6 gram sodium benzoate in per 500 milliliters anti-swine-fever serum, 800,000 unit penicillins, 3.5 milliliters of 600,000 unit chloromycetin and 0.3% carbolic acids.
4, serum composite according to claim 1 is characterized in that: add 3 gram sodium benzoate, 1,200,000 unit penicillins in per 500 milliliters of anti-swine-fever serums, 2 milliliters of 1,200,000 unit chloromycetin and 0.5% carbolic acids.
5, serum composite according to claim 1 is characterized in that: add 6 gram sodium benzoate in per 500 milliliters of anti-swine-fever serums, 800,000 unit penicillins, 3.5 milliliters of 500,000 unit chloromycetin and 0.4% carbolic acids.
6, serum composite according to claim 1 is characterized in that: add 4.5 gram sodium benzoate in per 500 milliliters anti-swine-fever serum, 1,600,000 unit penicillins, 5 milliliters of 800,000 unit streptomycins and 0.35% carbolic acids.
7, serum composite according to claim 1 is characterized in that: add 8 gram sodium benzoate in per 500 milliliters of anti-swine-fever serums, 400,000 unit penicillins, 2.5 milliliters of 1,200,000 unit chloromycetin and 0.5% carbolic acids.
8, the compound method of the serum composite of treatment swine fever is to make aseptic anti-swine-fever serum with hog cholera lapinised virus through 1～2 responsive pig of immune health earlier, it is characterized in that in aseptic anti-swine-fever serum, adding in any order sodium benzoate, penicillin, streptomycin or chloromycetin, carbolic acid, fully shake up to dissolving fully.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN89103922A CN1040923A (en) | 1989-06-08 | 1989-06-08 | Serum composite and compound method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN89103922A CN1040923A (en) | 1989-06-08 | 1989-06-08 | Serum composite and compound method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1040923A true CN1040923A (en) | 1990-04-04 |
Family
ID=4855340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN89103922A Pending CN1040923A (en) | 1989-06-08 | 1989-06-08 | Serum composite and compound method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1040923A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101031647B (en) * | 2004-02-27 | 2010-12-29 | 财团法人化学及血清疗法研究所 | Process for producing erysipelothrix rhusiopathiae surface protective antigen mutant in escherichia coli |
-
1989
- 1989-06-08 CN CN89103922A patent/CN1040923A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101031647B (en) * | 2004-02-27 | 2010-12-29 | 财团法人化学及血清疗法研究所 | Process for producing erysipelothrix rhusiopathiae surface protective antigen mutant in escherichia coli |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Axton | Six cases of poisoning after a parenteral organic mercurial compound (Merthiolate) | |
| Knudsen et al. | Cutaneous sensitivity to purified benzylpenicillin | |
| CN111494611A (en) | Interferon injection liquid packaged by cartridge bottle multi-dose pen type injection combination | |
| CN1958070A (en) | Triple high immunity immunoglobulin for anti transmissible gastroenteritis of pig, epidemic diarrhea of pig, and rotavirus of pig | |
| CN1100931A (en) | Treatment of viral infections | |
| CN1040923A (en) | Serum composite and compound method thereof | |
| RU2435571C1 (en) | Method of lymphotropic antibiotic therapy in case of inflammatory processes in organs of urinary excretion in females of domestic carnovores | |
| DE2334376A1 (en) | IMMUNOLOGICAL PRODUCT, ITS USE AND METHOD FOR ITS MANUFACTURING | |
| Teng et al. | Bacitracin levels in the cerebrospinal fluid after parenteral injections: Bacitracin therapy of experimental staphylococcal meningitis in the dog | |
| Chandar et al. | Falciparum malaria | |
| RU2256460C2 (en) | Method for treating inspecific bronchopneumonia in calves | |
| RU2486892C1 (en) | Method of lymphotropic therapy in case of orthodontal abscesses in rabbits | |
| RU2423996C1 (en) | Method of phytopreparation therapy of gastrointestinal diseases in calves | |
| SU1578735A1 (en) | Method of modeling peritonitis | |
| CN100577200C (en) | Medicine preparation for treating cow's mammitis and its preparation and use | |
| RU2063774C1 (en) | Method for treating the cases of chronic blood circulation disorders | |
| RU2228176C2 (en) | Method for treating mastitis in cows | |
| RM | The treatment of hypoplastic anaemia after chloramphenicol. | |
| WO1992020352A1 (en) | Means for treatment of diseases caused by microorganisms which is a solution of sodium thiosulphate and a weak acid and method of preparing it | |
| CN1748702A (en) | Newly packed naloxone hydrochloride injection and its producing method | |
| RU2214834C1 (en) | Method for treating generalized form of anthrax infection | |
| Petana | The action of oxytetracycline upon African trypanosomes in vitro | |
| AT334525B (en) | METHOD FOR PRODUCING HUMAN ANTISTAPHYLOCOCCUS IMMUNOGLOBULIN | |
| US5942224A (en) | Therapeutic agent for cat respiratory diseases and method of treatment using the same | |
| RU2005430C1 (en) | Method for treating osteomyelitis of lower extremities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |